Davis Polk advised Goldman, Sachs & Co. and Citigroup as joint book-running managers in connection with the $55 million initial public offering of common stock by Atara Biotherapeutics, Inc. Atara Biotherapeutics’ common stock is listed on the NASDAQ Global Select Market under the symbol “ATRA.” 

Based in Brisbane, California, Atara Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle-wasting conditions and oncology.  

The Davis Polk corporate team included partner Bruce K. Dallas and associates Aaron Justin Epstein and Jeffrey Hedrick. The tax team included partner Rachel D. Kleinberg and associate Patrick E. Sigmon. The intellectual property team included associates Jansen A. S. Thurmer and Nikita A. Tuckett. Counsel Cynthia Akard and Marcie A. Goldstein provided executive compensation and FINRA advice, respectively. Members of the Davis Polk team are based in the Menlo Park, New York and Washington DC offices.